Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
12 2019
Historique:
received: 23 05 2019
revised: 28 06 2019
accepted: 02 07 2019
pubmed: 23 8 2019
medline: 20 5 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

Accurate definition of the intraprostatic gross tumor volume (GTV) is crucial for diagnostic and therapeutic approaches in patients with primary prostate cancer (PCa). The optimal methodology for contouring of GTV using Prostate specific membrane antigen positron emission tomography (PSMA-PET) information has not yet been defined. PCa patients who underwent a [68Ga]PSMA-11-PET/CT followed by radical prostatectomy were prospectively enrolled (n = 20). Six observer teams with different levels of experience and using different PET image scaling techniques performed manual contouring of GTV. Additionally, semi-automatic segmentation of GTVs was performed using SUVmax thresholds of 20-50%. Coregistered histopathological gross tumor volume (GTV-Histo) served as reference. Inter-observer agreement was assessed by calculating the Dice similarity coefficient (DSC). Most contouring methods provided high sensitivity and specificity. For manual delineation, scaling the PET images from SUVmin-max: 0-5 resulted in high sensitivity (>86%). The highest specificity (100%) was obtained by scaling the PET images from SUVmin-max: 0-SUVmax. High interobserver agreement (median DSC 0.8) was observed when using the same PET image scaling technique (PET images SUVmin-max: 0-5). For semi-automatic segmentation, a low SUVmax threshold of 20% optimized sensitivity (SUVmax threshold 20%, 100% sensitivity, 32% of prostatic volume), whereas a higher threshold optimized specificity (SUVmax threshold 40%-50%, 100% specificity). Contouring of regions with high tracer-uptake resulted in very high specificities and should be used for biopsy guidance. Both manual and semi-automatic approaches using validated SUV scaling (SUVmin-max: 0-5) or thresholding (20%) may provide high sensitivity, and should be considered for PSMA-PET-based focal therapy approaches.

Identifiants

pubmed: 31431386
pii: S0167-8140(19)32981-0
doi: 10.1016/j.radonc.2019.07.002
pii:
doi:

Substances chimiques

Antigens, Surface 0
FOLH1 protein, human EC 3.4.17.21
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-213

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Constantinos Zamboglou (C)

Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Germany.

Thomas F Fassbender (TF)

Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany. Electronic address: thomas.fassbender@uniklinik-freiburg.de.

Lina Steffan (L)

Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.

Florian Schiller (F)

Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Tobias Fechter (T)

Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Montserrat Carles (M)

Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Selina Kiefer (S)

Department of Pathology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.

Hans C Rischke (HC)

Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.

Kathrin Reichel (K)

Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Nina-Sophie Schmidt-Hegemann (NS)

Department of Radiation Oncology, University Hospital, LMU Munich, Germany.

Harun Ilhan (H)

Department of Nuclear Medicine, University Hospital, LMU Munich, Germany.

Alin F Chirindel (AF)

Department of Radiology and Nuclear Medicine, University Hospital Basel, Switzerland.

Guillaume Nicolas (G)

Department of Radiology and Nuclear Medicine, University Hospital Basel, Switzerland.

Christoph Henkenberens (C)

Department of Radiation Oncology, Hannover Medical School, Germany.

Thorsten Derlin (T)

Department of Nuclear Medicine, Hannover Medical School, Germany.

Peter Bronsert (P)

Department of Pathology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.

Panayiotis Mavroidis (P)

Department of Radiation Oncology, University North Carolina - Chapel Hill, USA.

Ronald C Chen (RC)

Department of Radiation Oncology, University North Carolina - Chapel Hill, USA.

Philipp T Meyer (PT)

Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Juri Ruf (J)

Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany.

Anca L Grosu (AL)

Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine. University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH